Amarin (AMRN)
(Delayed Data from NSDQ)
$0.79 USD
0.00 (-0.49%)
Updated Jul 23, 2024 03:58 PM ET
After-Market: $0.79 0.00 (0.60%) 5:46 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMRN 0.79 0.00(-0.49%)
Will AMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMRN
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Other News for AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin gets reimbursement approval for Vazkepa in Portugal
Amarin gets reimbursement approval for Vazkepa in Portugal
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)